JP2002512800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512800A5 JP2002512800A5 JP2000546017A JP2000546017A JP2002512800A5 JP 2002512800 A5 JP2002512800 A5 JP 2002512800A5 JP 2000546017 A JP2000546017 A JP 2000546017A JP 2000546017 A JP2000546017 A JP 2000546017A JP 2002512800 A5 JP2002512800 A5 JP 2002512800A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- polynucleotide
- nucleotide sequence
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 108091033319 polynucleotide Proteins 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 208000034762 Meningococcal Infections Diseases 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9808866.9 | 1998-04-24 | ||
| GBGB9808866.9A GB9808866D0 (en) | 1998-04-24 | 1998-04-24 | Novel compounds |
| PCT/EP1999/002766 WO1999055873A2 (en) | 1998-04-24 | 1999-04-20 | Basb006 polynucleotide(s) and polypeptides from neisseria meningitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010044312A Division JP2010166920A (ja) | 1998-04-24 | 2010-03-01 | 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002512800A JP2002512800A (ja) | 2002-05-08 |
| JP2002512800A5 true JP2002512800A5 (enExample) | 2006-04-27 |
| JP4718009B2 JP4718009B2 (ja) | 2011-07-06 |
Family
ID=10830985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000546017A Expired - Fee Related JP4718009B2 (ja) | 1998-04-24 | 1999-04-20 | 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド |
| JP2010044312A Pending JP2010166920A (ja) | 1998-04-24 | 2010-03-01 | 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010044312A Pending JP2010166920A (ja) | 1998-04-24 | 2010-03-01 | 髄膜炎菌由来のｂａｓｂ００６ポリヌクレオチドおよびポリペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6696062B1 (enExample) |
| EP (2) | EP2360260A1 (enExample) |
| JP (2) | JP4718009B2 (enExample) |
| CN (1) | CN1203180C (enExample) |
| AU (1) | AU3928499A (enExample) |
| CA (1) | CA2326375A1 (enExample) |
| GB (1) | GB9808866D0 (enExample) |
| WO (1) | WO1999055873A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| CA2671261A1 (en) * | 1997-11-06 | 1999-05-20 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens |
| GB9808866D0 (en) * | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| WO2001031019A2 (en) | 1999-10-29 | 2001-05-03 | Chiron Spa | Neisserial antigenic peptides |
| GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| CA2838395C (en) | 1999-05-19 | 2016-07-19 | Novartis Vaccines And Diagnostics S.R.L. | Combination neisserial compositions |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| CN102172398A (zh) | 2000-01-17 | 2011-09-07 | 诺华疫苗和诊断有限公司 | 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗 |
| DE60144353D1 (de) | 2000-02-28 | 2011-05-12 | Novartis Vaccines & Diagnostic | Hybride Expression Neisserscher Proteine |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| PT2248822T (pt) | 2001-07-27 | 2017-02-14 | Glaxosmithkline Biologicals Sa | Adesinas de meningococos |
| AU2003260357B2 (en) | 2002-08-02 | 2009-10-29 | Glaxosmithkline Biologicals S.A. | Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis |
| RU2317106C2 (ru) * | 2002-08-02 | 2008-02-20 | ГлаксоСмитКлайн Байолоджикалз с.а. | Нейссериальные вакцинные композиции, содержащие комбинацию антигенов |
| HUE047780T2 (hu) | 2002-10-11 | 2020-05-28 | Glaxosmithkline Biologicals Sa | Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre |
| AU2004277342B2 (en) | 2003-10-02 | 2010-12-16 | Glaxosmithkline Biologicals S.A. | Pertussis antigens and use thereof in vaccination |
| US20080280987A1 (en) * | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| AU2009262893B2 (en) | 2008-05-30 | 2015-05-21 | The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research | Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof |
| BR112012022669A2 (pt) | 2010-03-10 | 2017-02-14 | Glaxosmithkline Biologicals Sa | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
| ES2663872T3 (es) | 2010-03-11 | 2018-04-17 | Glaxosmithkline Biologicals S.A. | Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB9022190D0 (en) | 1990-10-12 | 1990-11-28 | Perham Richard N | Immunogenic material |
| FR2682041B1 (fr) * | 1991-10-03 | 1994-01-14 | Pasteur Merieux Serums Vaccins | Vaccin contre les infections a neisseria meningitidis. |
| EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| ES2109685T5 (es) | 1993-03-23 | 2005-09-01 | Smithkline Beecham Biologicals S.A. | Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado. |
| US5747292A (en) | 1993-04-06 | 1998-05-05 | Fred Hutchinson Cancer Research Center | Chimeric cytokine receptors in lymphocytes |
| JPH08508889A (ja) | 1993-06-07 | 1996-09-24 | アムジエン・インコーポレーテツド | ハイブリッドレセプター分子 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6245337B1 (en) * | 1994-08-25 | 2001-06-12 | Washington University | Haemophilus adherence and penetration proteins |
| US6121037A (en) * | 1994-10-18 | 2000-09-19 | Stojiljkovic; Igor | Bacterial hemoglobin receptor genes |
| US6265567B1 (en) * | 1995-04-07 | 2001-07-24 | University Of North Carolina At Chapel Hill | Isolated FrpB nucleic acid molecule |
| EP0821737A4 (en) * | 1995-04-21 | 2005-01-19 | Human Genome Sciences Inc | NUCLEOTIDE SEQUENCE OF THE GENOME HAEMOPHILUS INFLUENZAE RD, THE FRAGMENTS THEREOF, AND ITS APPLICATIONS |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
| EP0939647B2 (en) * | 1996-08-27 | 2006-07-12 | Chiron Corporation | Neisseria meningitidis serogroup b glycoconjugates and methods of using the same |
| CA2671261A1 (en) * | 1997-11-06 | 1999-05-20 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens |
| US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| GB9808734D0 (en) * | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| GB9808866D0 (en) * | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| WO2000055327A2 (en) * | 1999-03-12 | 2000-09-21 | Smithkline Beecham Biologicals S.A. | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| GB0025171D0 (en) * | 2000-10-13 | 2000-11-29 | Smithkline Beecham Biolog | Novel compounds |
| PT2248822T (pt) * | 2001-07-27 | 2017-02-14 | Glaxosmithkline Biologicals Sa | Adesinas de meningococos |
-
1998
- 1998-04-24 GB GBGB9808866.9A patent/GB9808866D0/en not_active Ceased
-
1999
- 1999-04-20 AU AU39284/99A patent/AU3928499A/en not_active Abandoned
- 1999-04-20 CN CNB998077712A patent/CN1203180C/zh not_active Expired - Fee Related
- 1999-04-20 EP EP10011715A patent/EP2360260A1/en not_active Withdrawn
- 1999-04-20 WO PCT/EP1999/002766 patent/WO1999055873A2/en not_active Ceased
- 1999-04-20 EP EP99922122A patent/EP1071783A2/en not_active Withdrawn
- 1999-04-20 JP JP2000546017A patent/JP4718009B2/ja not_active Expired - Fee Related
- 1999-04-20 CA CA002326375A patent/CA2326375A1/en not_active Abandoned
- 1999-04-20 US US09/673,896 patent/US6696062B1/en not_active Expired - Fee Related
-
2003
- 2003-12-19 US US10/742,345 patent/US7419824B2/en not_active Expired - Fee Related
-
2008
- 2008-07-25 US US12/180,055 patent/US20100196409A1/en not_active Abandoned
-
2010
- 2010-03-01 JP JP2010044312A patent/JP2010166920A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002512800A5 (enExample) | ||
| JP2693145B2 (ja) | 乳頭腫ウイルス型特異的抗体 | |
| Svehag et al. | THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY: II. 19S and 7S Antibody Formation: Differences in Antigen Dose Requirement for Sustained Synthesis, Anamnesis, and Sensitivity to X-Irradiation | |
| KR860700090A (ko) | 어드헤신(Adhesin)항원 | |
| JPS61289888A (ja) | ワクシニアｄｎａ | |
| RU99122686A (ru) | Модифицированные молекулы фно альфа, днк, кодирующие эти модифицированные молекулы фно альфа, и вакцины, включающие эти модифицированные молекулы фно альфа и днк | |
| CN86102858A (zh) | 制备猪支原体的重组表面抗原及其疫苗的方法 | |
| JP2006523453A5 (enExample) | ||
| JPH09505723A (ja) | ４３ｋｄヒトガン抗原からの免疫反応性ペプチド配列 | |
| BG64627B1 (bg) | Нсv геномни последователности за диагностика и лечение | |
| US20090074781A1 (en) | Dengue virus peptide vaccine and methods of preparing and using the same | |
| IL139613A (en) | Compositions of polynucleotide (s) basb029 and polypeptides of neisseria meningitidis, methods of production and their uses | |
| CA2217522A1 (en) | Isolated frpb nucleic acid molecule and vaccine | |
| WO2022071513A1 (ja) | ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン | |
| CN113186223A (zh) | 一种新冠病毒疫苗的表达载体及其构建方法、应用和疫苗 | |
| JP4820489B2 (ja) | ヒト型結核菌により発現され且つｂｃｇによって発現されないタンパク質、ならびに診断薬およびワクチンとしてのそれらの使用 | |
| CN116970058B (zh) | 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用 | |
| CA2719041C (en) | A method for identifying polypeptides which comprise a cross-reactive antigenic determinant | |
| JPH05501401A (ja) | 組換え微生物との転移増殖によるワクチン又はトキソイド製剤及び免疫の方法 | |
| JP2003533990A (ja) | 百日咳菌、パラ百日咳菌および気管支敗血症菌のペルタクチンの繰返し領域の多型性を有するポリペプチド、ならびに診断および免疫原性組成物におけるその使用 | |
| KR101845571B1 (ko) | 전통적 돼지열에 대한 마커 백신 | |
| JPH08510714A (ja) | エプスタイン−バーウィルスからの免疫反応性ペプチド | |
| CN111138553B (zh) | 一种融合蛋白及一种弓形虫亚单位疫苗及其疫苗组合物 | |
| CN117024522A (zh) | 针对pik3ca基因e545k突变的肿瘤新抗原多肽及其应用 | |
| DE60025522T2 (de) | Mycoplasma mycoides subsp. mycoides sc antigenisches lppq protein, seine herstellung und verwendung |